Golixter 120mg

GOLIXTER 120 MG Product Overview Golixter 120 mg Tablet contains Relugolix, an oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist used in the management of advanced prostate cancer. It works by blocking GnRH receptors in the anterior pituitary gland, which suppresses the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately reducing testosterone levels in men. […]

Enzter 160

Enzter 160 Composition Generic name: Enzalutamide Dosage forms: 160 mg Drug classes: Antiandrogens, Hormones Indications Castration-resistant prostate cancer (CRPC) Metastatic castration-sensitive prostate cancer (CSPC) Non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) Dosage 160 mg PO Day CRPC or CSPC: Patients should also receive a gonadotropic-releasing hormone (GnRH) […]

Abifort 500

Abifort Indication Abiraterone acetate is indicated in combination with methylprednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC)3 or with prednisone for the treatment of metastatic CRPC or metastatic high-risk castration-sensitive prostate cancer (CSPC) Mechanism Of Action Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 […]

Lutarun 50

Lutarun Description Bicalutamide tablets for oral administration contain 50 mg of bicalutamide, a nonsteroidal antiandrogen with no other known endocrine activity. The chemical name is propanamide, N-[4-cyano-3-(trifluoromethy1)pheny1]-3-[4-fluoropheny1)sulfony1]-2-hydroxy-2-methy1-,(+-). Bicalutamide molecular formula is C18H14N2O4F4S. Bicalutamide is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive. Pharmacology […]

Lupter 22.5

Lupter Leuprolide Acetate for Injection (Depot) 22.5mg Prostate Cancer Leuprolide acetate for Injection (Depot) is indicated in the palliative treatment of advanced prostatic cancer. It offers an alternative treatment when orchidectomy or estrogen administration is either not indicated or unacceptable to the patient. Administered 3-monthly as a single intramuscular injection. Therapy should not be discontinued […]